Standard Biotools Inc (LAB) Return on Assets ROA from the second quarter of 2026 to second quarter of 2025 and for the year 2026, Average High and Low, Fundamental Ratios from Jun 30 2026 to Jun 30 2025 - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Standard Biotools Inc   (NASDAQ: LAB)


Standard Biotools Inc 's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics


What is Standard Biotools Inc 's ROA in the second quarter of 2026?
Standard Biotools Inc achieved a return on average assets (ROA) of 14.32 % in its second quarter of 2026, this is above LAB's average return on assets of -20.15%.
Standard Biotools Inc assets over the 12 months ending in its second quarter of 2026 are valued at $593 million

Despite the company's net income deteriorating, Standard Biotools Inc was able to improve its ROA compared to the first quarter of 2026.

However, within the Healthcare sector 68 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 407, from total ROA ranking in the first quarter of 2026 at 3868.

What is ROA?


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Assets (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter		 (Jun 30 2025)
II. Quarter
Y / Y Total Assets Change 12.24 % 10.27 % 1.71 % -17.4 % -17.84 %
Y / Y Net Income Change - - - - -
Net Income (TTM) in million 85 78 -75 -128 -121
Return On Assets (TTM) 14.32 % 13.58 % -13.35 % -22.96 % -20.53 %
LAB's Total Ranking # 407 # 3868 # 3595 # 3577 # 3633
Total Assets (TTM) in million 625 639 568 540 557
Seq. Total Assets Change -2.19 % 12.57 % 5.21 % -3.11 % -3.9 %
Seq. Net Income Change - 558.96 % - - -

LAB's 5 Years Annual ROA >> Back to LAB Management Effectiveness >> Compare LAB ROA to its Competitors


Return On Assets Company Ranking
Within: No.
Industry # 1
Sector # 69
Overall # 378

Return On Assets Statistics
High Average Low
14.31 %
-20.15 %
-51.35 %
(Jun 30 2026)   (Jun 30 2022)



  News about Standard Biotools Inc Return on Assets ROA

Standard BioTools Strengthens Leadership and Financial Strategy Amidst Third Quarter Challenges

In a move signaling its commitment to robust fiscal management and operational insight, Standard BioTools Inc. has appointed Alex Kim as Chief Financial Officer, effective November 11, 2024. This strategic decision comes against the backdrop of the company’s unveiling of its third-quarter financial results, presenting a moment of both challenge and opportunity within the competitive landscape of laboratory instrumentation.Alex Kim, a co-founder of Standard BioTools and the previous Chief Operating Officer, steps into the CFO role with nearly three decades of experience in finance and operations within the healthcare and life sciences sectors. His extensive background positions him effectively to deliver strategic oversight of the company’s finance organization, thereby ensuring that Standard BioTools capitalizes on current market dynamics while addressing any operational challenges head-on.

Revitalizing Operational Excellence: Standard BioTools Spearheads Biotech Innovations for a Sustainable Future

Standard BioTools Announces Operational Restructuring Plan to Drive Long-Term Profitable Growth
SOUTH SAN FRANCISCO, Calif., April 25, 2024 - Standard BioTools Inc. (Standard BioTools or the Company) (Nasdaq: LAB) today announced that it has initiated a restructuring plan to improve operational efficiency and reduce operating costs, while supporting the execution of the Company s long-term strategic plan.
This comes as no surprise, as numerous companies across industries have been forced to reassess their operations amidst the ever-evolving market dynamics. In an effort to remain competitive, Standard BioTools has undertaken this proactive approach to optimize its operations, align with changing industry trends, and enhance profitability.



Financial Statements
Standard Biotools Inc 's Assets $ 625 million LAB's Balance sheet
Standard Biotools Inc 's Income $ -27 million Quarterly LAB's Income Statement
LAB's Income by Division See LAB's Income by Division



Annual Return On Assets (Dec 31 2025)
FY 2025		 (Dec 31 2024)
FY 2024		 (Dec 31 2023)
FY 2023		 (Dec 31 2022)
FY 2022		 (Dec 31 2021)
FY 2021
Y / Y Total Assets Change 1.15 % 99.47 % -18.15 % 50.09 % -16.86 %
Total Assets in million 593 587 294 359 239
Y / Y Net Income Change - - - - -
Net Income in million -75 -139 -75 -190 -59
Annual Return On Assets -12.62 % -23.67 % -25.38 % -52.91 % -24.74 %

LAB's 5 Years Annual ROA >> Back to LAB Management Effectiveness >> Compare LAB ROA to its Competitors



More Return On Assets Ratios
LAB's' Return on Assets at Yahoo Finance
Laboratory Analytical Instruments Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
LAB's Roa Ratio versus Laboratory Analytical Instruments Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for LAB's Competitors
Subscribers only: Roa for Standard Biotools Inc 's Suppliers
Subscribers only: Return On Assets for LAB's Customers

You may also want to know
LAB's Roi LAB's Inventory Turnover Ratio LAB's Growth Rates LAB's Dividend Comparisons
LAB's Profitability Ratios LAB's Asset Turnover Ratio LAB's Dividend Growth
LAB's Roe LAB's Valuation Ratios LAB's Financial Strength Ratios LAB's Dividend Payout Ratio



Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector ROA
Liquidia Corporation  36.30 %
Ironwood Pharmaceuticals inc   34.34 %
Idexx Laboratories Inc  33.61 %
Tg Therapeutics Inc   33.59 %
Meiragtx Holdings Plc  29.37 %
Indivior Pharmaceuticals Inc   28.21 %
Qhslab Inc   27.12 %
Adma Biologics Inc   26.58 %
Mettler toledo International Inc   24.86 %
Medpace Holdings Inc   24.84 %
Caredx Inc   24.81 %
Acadia Pharmaceuticals Inc   24.38 %
Eli Lilly And Company  21.97 %
Innoviva Inc   21.64 %
Vaxart Inc   20.85 %
Zevra Therapeutics Inc   20.39 %
Iradimed Corporation  20.36 %
Protalix Biotherapeutics inc   20.09 %
Pro dex Inc   19.87 %
Electromed Inc   19.39 %
United Therapeutics Corporation  17.98 %
Resmed Inc   17.80 %
Krystal Biotech Inc   17.65 %
Chemed Corporation  17.52 %
Zoetis Inc   17.19 %
Vertex Pharmaceuticals Inc  16.88 %
Halozyme Therapeutics Inc   16.55 %
Alnylam Pharmaceuticals Inc   15.76 %
Intuitive Surgical Inc   15.63 %
Healthcare Services Group Inc   15.21 %

Date modified: 2026-09-01T20:00:47+00:00


Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.